Effectiveness of the addition of the brain region to the FDG-PET/CT imaging area in patients with suspected or diagnosed lung cancer

Basit Öğe Kaydı
dc.contributor.authorTasdemir, Bekir
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorDostbil, Zeki
dc.contributor.authorUnal, Kemal
dc.contributor.authorSimsek, F. Selcuk
dc.contributor.authorTeke, Fatma
dc.contributor.authorGoya, Cemil
dc.date.accessioned2024-04-24T16:02:29Z
dc.date.available2024-04-24T16:02:29Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose We aimed to evaluate the effectiveness of the brain region imaging in FDG-PET/CT scanning of patients with suspected or diagnosed lung cancer. Materials and methods We performed the study retrospectively on the medical charts of 427 patients. We divided the FDG-PET/CT field of view (FOV) into four major imaging regions: brain, head-neck, abdomen and pelvis. Metastatic findings on these regions were checked and determined the potential of these findings to affect the chemotherapy or radiotherapy protocol or surgical management. If metastatic findings had a potential to modify these parameters, we named this situation as clinical contribution. Considering the number of bed positions of these regions, we calculated the clinical contribution of each region and named as effective clinical contribution. Then, we calculated the metastatic findings, clinical contribution, and effective clinical contribution ratios. Results We found different brain metastasis ratios for lung cancer, solitary pulmonary mass (SPM), and solitary pulmonary nodule (SPN) groups (8.7, 2.8 and 0.9 %, respectively). In addition, the clinical contribution and effective clinical contribution ratios in the brain region for these three groups were 6.4, 2.8, 0.0 and 6.4, 2.8, 0.0 %, respectively. The highest metastatic findings (30.6 %) and clinical contribution (9.8 %) ratios were found in the abdomen region of the lung cancer group. However, the highest effective clinical contribution ratio (6.8 %) was found in the brain region within the same group. Conclusions The addition of the brain region to the limited whole-body FOV in FDG-PET/CT scanning seems to be effective in the lung cancer and SPM groups, but not in the SPN group.en_US
dc.identifier.doi10.1007/s11547-015-0597-y
dc.identifier.endpage224en_US
dc.identifier.issn0033-8362
dc.identifier.issn1826-6983
dc.identifier.issue3en_US
dc.identifier.pmid26541882
dc.identifier.scopus2-s2.0-84958104333
dc.identifier.scopusqualityQ1
dc.identifier.startpage218en_US
dc.identifier.urihttps://doi.org/10.1007/s11547-015-0597-y
dc.identifier.urihttps://hdl.handle.net/11468/14807
dc.identifier.volume121en_US
dc.identifier.wosWOS:000370719300008
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofRadiologia Medica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPositron Emission Tomographyen_US
dc.subjectField Of Viewen_US
dc.subjectBrainen_US
dc.subjectLung Canceren_US
dc.subjectSolitary Pulmonary Noduleen_US
dc.subjectSolitary Pulmonary Massen_US
dc.titleEffectiveness of the addition of the brain region to the FDG-PET/CT imaging area in patients with suspected or diagnosed lung canceren_US
dc.titleEffectiveness of the addition of the brain region to the FDG-PET/CT imaging area in patients with suspected or diagnosed lung cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu